#### **Running Title:** Atrial Fibrillation Expenditures in the US

Healthcare Expenditure on Atrial Fibrillation in the United States:

The Medical Expenditure Panel Survey 2016-2021

Claudia See MD MBA<sup>1</sup>, Scott Grubman MD MHS<sup>2</sup>, Nisarg Shah BS<sup>3</sup>, Jiun-Ruey Hu<sup>4</sup>, Michael

Nanna, MD, MHS<sup>5</sup>, James V. Freeman MD, MPH, MS<sup>5,6</sup>, Karthik Murugiah MBBS<sup>5,6</sup>

<sup>1</sup>Division of General Internal Medicine, University of California, San Francisco, CA

<sup>2</sup>Division of General Internal Medicine, The Mount Sinai Hospital, New York, NY

<sup>3</sup>Yale School of Medicine, New Haven, CT

<sup>4</sup>Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

<sup>5</sup>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT

<sup>6</sup>Center for Outcomes Research and Evaluation, Yale New Haven Health Services Corporation, New Haven, Connecticut, USA

Word Count: 3,333

**Financial Support:** Dr. See received support from the Yale School of Medicine 2023 Fellowship for Medical Student Research. Dr. Murugiah received support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under award K08HL157727). Dr. Nanna reports research support from the American College of Cardiology (George F and Ann Harris Bellows Foundation), the Patient-Centered Outcomes Research Institute, the Yale Claude D. Pepper Older Americans Independence Center (P30AG021342),

and the National Institute on Aging/National Institutes of Health (GEMSSTAR award: R03AG074067).

**Relationship with Industry:** Dr. Freeman reports research support from the NIH/NHLBI and the American College of Cardiology National Cardiovascular Data Registry and advisory board/consulting with Boston Scientific, Medtronic, Abbott, Biosense Webster, and PaceMate. Dr. Nanna reports consulting from HeartFlow, Inc., Novo Nordisk, and Merck.

# Address for Correspondence:

Claudia See, MD MBA 1239 4th Ave, San Francisco, CA 94122 Tel: 858 472 7605. <u>claudia.see@ucsf.edu</u>.

### **ABSTRACT:**

**Objectives:** To provide a contemporary nationally representative assessment of atrial fibrillation (AF) and atrial flutter (AFL) expenditures in the United States.

**Background:** AF prevalence is rising over time and management is evolving. However, there has been no contemporary national assessment of expenditures of AF.

**Methods:** Using Medical Expenditure Panel Survey (MEPS) 2016-2021 data, we identified individuals with AF or AFL using International Classification of Disease (ICD)-10 codes and reported total and categorized expenditures. Using two-part and gamma regression models, respectively, we estimated the incremental expenditures with AF for the entire population and for individuals with common coexisting comorbidities. Among individuals with AF, we identified characteristics associated with higher expenditures.

**Results:** Of a weighted surveyed population of 248,067,064 adults, 3,564,763 (1.4%) had AF. Mean age was  $71.9 \pm 10.6$  years and 45.7% were female. Mean unadjusted annual total healthcare expenditure for individuals with AF was  $25,451 \pm 1,100$  compared with  $9,254 \pm$ 82 for individuals without AF. The highest spending categories were inpatient visits ( $7,975 \pm$ 733) and prescriptions ( $6,505 \pm 372$ ). AF expenditures increased over the study period by 11.1%. After adjustment, the incremental annual expenditure attributable to AF was 6,188 per person. Incremental expenditures with AF were highest for those with cancer (11,967,95% CI 4,410 - 19,525), while AF did not significantly increase expenditures in HF (-2,756,95% CI -10,048 - 4,535). Modified Charlson Comorbidity Index of 1 or  $\geq 2$ , uninsured status, cancer, poor income level, ASCVD, COPD, and later survey year were associated with higher expenditures.

Conclusion: AF is associated with substantial healthcare expenditures which are increasing over

time. With changes in screening and management, expenditures need periodic reassessments.

Word Count: 272

# **CONDENSED ABSTRACT:**

**Introduction:** AF prevalence is rising, but contemporary national expenditure assessments are lacking.

Methods: Two-part and gamma regression models of MEPS 2016-2021 data (all-payer cross-

sectional US survey) estimated AF effect on healthcare expenditures.

Results: Of 248,067,064 adults, 1.4% had AF, with mean age 72.1 years and 45.7% female.

Mean unadjusted annual expenditure was  $25,451 \pm 1,100$  ( $9,254 \pm 82$  without AF).

Incremental adjusted annual expenditure attributable to AF was \$6,188. Modified CCI of 1 or

≥2, uninsured status, cancer, poor income level, ASCVD, COPD, and later survey year were

associated with higher expenditure.

Discussion: AF expenditures are substantial and increasing.

Word Count: 99

# **Condensed Abstract Abbreviations:**

- AF = Atrial Fibrillation
- CCI = Charlson Comorbidity Index
- MEPS = Medical Expenditure Panel Survey
- NHEA = National Health Expenditure Accounts
- US = United States

# **Manuscript Abbreviations:**

- AAD = Antiarrhythmic Drug
- AF = Atrial Fibrillation
- AHRQ = Agency of Healthcare Research and Quality
- ASCVD = Atherosclerotic Cardiovascular Disease
- CABANA = Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation
- CCI = Charlson Comorbidity Index
- COPD = Chronic Obstructive Pulmonary Disease
- CPI = Consumer Price Index
- DOAC = Direct-Acting Oral Anticoagulants
- ED = Emergency Department
- FPL = Federal Poverty Line
- GED = General Educational Development
- HF = Heart Failure
- HS = High School
- MEPS = Medical Expenditure Panel Survey
- NCHS = National Center for Health Statistics
- NHEA = National Health Expenditure Accounts
- NHIS = National Health Interview Survey
- OR = Odds Ratio
- SD = Standard Deviation
- US = United States
- IQR = Interquartile Range

### 1 **INTRODUCTION**

2 Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting between 2.7 to 6.1 3 million people in the United States (US) (1). Over time, with an aging population and potentially 4 increased detection due to improved and more widespread monitoring devices, the prevalence of 5 AF has been rising and the prevalence is estimated to be 12.1 million by 2030 (2). 6 7 AF is associated with significant morbidity, including hospitalizations and risk for cardiovascular 8 and cerebrovascular events (3,4). Given these characteristics, AF is associated with high 9 healthcare expenditures (5,6). The management of AF has been evolving, with increased use of 10 antiarrhythmics and procedures to maintain sinus rhythm as well as increased use of direct-acting

11 oral anticoagulants (DOACs) and left atrial appendage occlusion for stroke prevention, which

12 can also affect expenditures. However, contemporary studies of US national healthcare

13 expenditures for AF care have been lacking. Further, AF frequently co-exists with other

14 important cardiac and non-cardiac comorbidities such as heart failure (HF), atherosclerotic

15 cardiovascular disease (ASCVD), chronic obstructive pulmonary disease (COPD), and cancer,

16 all of which may complicate their management (7-9). How contemporary expenditures of these

17 conditions are influenced by co-existent AF has not been well evaluated.

18

Accordingly, the aim of this study was to report current annual healthcare expenditures and
recent trends for individuals with AF (categorizing expenditures across medical service
categories such as hospitalizations and prescriptions), estimate the incremental expenditures
nationally attributable to AF, and identify the characteristics of individuals with AF who
experience higher expenditures.

# 24 METHODS

### 25 Data Sources

26	The Medical Expenditure Panel Survey (MEPS) is an annual cross-sectional survey of US
27	families and individuals by the Agency of Healthcare Research and Quality (AHRQ). It is the
28	largest all-payer nationally representative annual cross-sectional survey of medical expenditures
29	of the US civilian, noninstitutionalized population (10). MEPS collects data on demographic
30	characteristics, health conditions, health status, use of medical services, charges and source of
31	payments, access to care, satisfaction with care, health insurance coverage, income, and
32	employment. Overall response rates in the years 2016 to 2021 were approximately 22-46% (11).
33	
34	The panel design of the survey includes 5 rounds of interviews covering 2 full calendar years.
35	Every year, a new panel of about 15,000 sample households is selected. The set of households
36	selected for each panel is a subsample of households participating in the previous year's National
37	Health Interview Survey (NHIS) conducted by the National Center for Health Statistics (NCHS).
38	
39	Data from the MEPS Household Component Full-Year Consolidated Data Files and Medical
40	Conditions Files were pooled across the years 2016 to 2021 and then merged using two
41	variables-patient identifier variable 'DUPERSID' and survey 'Year.' The study was limited to
42	2016 and after because the ICD-9 codes used in MEPS data before 2016 were limited to three-
43	digits for confidentiality reasons and could not distinguish AF from other cardiac arrhythmias.
44	For 2016 and 2017, the two-digit panel number from variable 'PANEL' was added in front of all
45	DUPERSIDs per the recommendation of AHRQ (12) to be consistent across all survey years.
46	Families and individuals were assigned weights based on demographic proportions in the overall

47	US population (13). The NHIS sample design underwent several changes between 2016-2021,
48	such as discontinuation of oversampling of Asian, Black, and Hispanic minority groups (14) in
49	favor of oversampling of Veterans and middle-sized states (15,16). To compensate for low
50	response rates during the COVID-19 pandemic, MEPS extended the duration of its survey panels
51	by one year (11).

52

53 As all data and materials are de-identified and publicly available online

at https://meps.ahrq.gov/mepsweb/, this study was exempt from institutional review board

55 approval by Yale University.

#### 56 Study Population

57 The study population included all adults aged 18 years old or older. AF and atrial flutter (AFL)

58 was identified using the International Classification of Disease (ICD)-10 code "I48." Similarly,

59 ASCVD, HF, COPD, and cancer were identified using appropriate ICD-10 codes (see

60 Supplemental Table 1). The weighted population size was estimated as the average annual

61 population size for the pooled period, based on the recommendation from AHRQ on pooling

**62** (17).

63

### 64 Variables and Pre-Processing

Age was categorized into 18-44, 45-64, 65-84, and  $\geq$ 85 years old, and sex as male or female.

66 Race/ethnicity was categorized as non-Hispanic White, Hispanic, non-Hispanic Black, and non-

67 Hispanic Asian and other/mixed race. Marital status was categorized as married, never married,

68 and divorced/widowed/separated. Insurance status was categorized as private, Medicare, other

69	public, or uninsured. Education was categorized as no degree, general educational development
70	(GED) or high school (HS) graduate, bachelor's degree, master or doctorate degree, and other
71	degree. Family income was categorized as poor (families with income less than or equal to the
72	federal poverty line [FPL]), near-poor (100-125% of the FPL), low income (125-200% of the
73	FPL), middle income (200-400% of the FPL), and high income (>400% of the FPL) per the
74	MEPS poverty status variable. In the multivariable models, age and survey year were treated as
75	continuous variables. The Stata 'charlson' package was used to calculate the Charlson
76	Comorbidity Index (CCI) score (18). A higher score represents more comorbid conditions.
77	
78	Total medical expenditure was defined as the sum of direct payments for care across 8 medical
79	service categories: inpatient hospitalization stays, outpatient and office-based visits, prescription
80	medication, emergency department (ED) visits, dental visits, home healthcare, and others
81	(including dental and vision expenditures). Payments were combined across 10 payers such as
82	private insurance, Medicare, Medicaid, Tricare, out-of-pocket, and other. All expenditures and
83	incomes in our analyses were inflation adjusted to year 2021 using the Consumer Price Index
84	(CPI). Home health expenditures were derived by summed home health agency and home health
85	non-agency expenditure MEPS variables. Other expenditures were derived by summed dental,

86 vision, and 'other' expenditure MEPS variables.

### 87 Statistical Methods

88 Continuous variables were presented as mean  $\pm$  standard deviation (SD) and categorical

89 variables as proportions. Continuous and categorical variables were compared using the

90 Wilcoxon rank-sum test and chi-squared tests, respectively. A two-sided p-value of <0.05 was

91 used for statistical significance. MEPS survey weights were applied using the 'svy' function in

92 Stata. Statistical analysis was conducted using Stata Statistical Software: Release 18 (College
93 Station, TX).

94

# 95 Modeling Healthcare Expenditure

96 For expenditure data which are typically right-skewed (19), a two-part model is commonly

97 used—the first model is a logistic or probabilistic (probit) regression model which estimates the

98 probability of zero versus positive expenditures, and the second model, conditional on having a

99 positive annual healthcare expenditure, such as a generalized linear model with gamma

100 distribution and a logarithmic-link function that estimates the average expenditure per capita

101 (20,21).

102

103 Accordingly, to estimate incremental total healthcare expenditure attributable to AF, a two-part

regression model was created using the entire pooled population with and without AF.

105 Covariates included in multivariable adjustment were AF, age, sex, race/ethnicity, survey year,

106 CCI, poverty level, education status, marital status, and insurance status. National estimates of

107 AF expenditure were extrapolated by multiplying the incremental expenditure per person by the

108 survey weighted number of individuals with AF in the US in our study.

109

Second, incremental expenditures attributable to AF within subpopulations of individuals with 4 other common chronic comorbidities of cancer, ASCVD, COPD, and HF were estimated by creating a gamma regression model for each subpopulation and calculating average marginal effect with 95% confidence intervals (CI). Gamma models were used instead of two-part models because of the low prevalence of individuals with no expenditures within the comorbidity

115	subpopulations. For these gamma regression models, a 'modified' CCI was used by excluding
116	the 4 comorbidities of ASCVD, cancer, HF, and COPD (22), resulting in 3 final score categories
117	of 0, 1, and $\geq$ 2. This was done to enable inputting these comorbidities as separate covariates into
118	the model to study their individual effects.
119	
120	Third, individual characteristics associated with increased total healthcare expenditures were
121	determined by creating a gamma regression model only for individuals with AF and calculating
122	odds ratios (OR) with 95% CI. For this gamma regression model, the 'modified' CCI covariate
123	was also used.
124	
125	RESULTS
126	Study Population Characteristics
127	The average annual surveyed population was 22,911 US adults aged $\geq 18$ years. Of these, 98.6%
128	had complete data (n=22,583), equivalent to a survey weighted population of 248,067,064 adults.
129	Within this population with complete data, 1,902 survey respondents had AF, equivalent to a
130	survey weighted population of 3,564,763 adults and an overall AF prevalence of 1.4%.
131	
132	
132	Table 1 shows demographics and comorbidities of the overall population, with and without AF.
133	Table 1 shows demographics and comorbidities of the overall population, with and without AF. Among individuals with AF, the mean age was $71.9 \pm 10.6$ years, 45.7% were female, and
133	Among individuals with AF, the mean age was $71.9 \pm 10.6$ years, 45.7% were female, and
133 134	Among individuals with AF, the mean age was $71.9 \pm 10.6$ years, $45.7\%$ were female, and 89.0% were non-Hispanic white. The median CCI was 1 (Interquartile Range [IQR] 0-1).
133 134 135	Among individuals with AF, the mean age was $71.9 \pm 10.6$ years, $45.7\%$ were female, and $89.0\%$ were non-Hispanic white. The median CCI was 1 (Interquartile Range [IQR] 0-1). Among individuals without AF, the mean age was $47.5 \pm 18.2$ years, $51.8\%$ were female, and

138 12.6% vs. 3.4%, COPD 9.5% vs. 2.2%, and HF 7.0% vs. 0.6% respectively (all p<0.001).

139

### 140 Healthcare Expenditures with AF

- 141 For individuals with AF, the mean unadjusted annual total healthcare expenditure in terms of
- 142 2021 inflation-adjusted dollars was  $$25,451 \pm $1,100$  (Table 1) compared with  $$9,254 \pm $82$  for
- 143 individuals without AF (p<0.001). The highest expenditures among service categories in AF

144 were inpatient visits ( $$7,975 \pm $733$ ), followed by prescriptions ( $$6,505 \pm $372$ ) and office-

- based visits ( $$4,716 \pm $247$ ). Annual expenditures for individuals with AF were higher than
- 146 those without AF across all service categories.

147

In comparison, mean unadjusted annual total healthcare expenditure among individuals with
other chronic diseases - HF, cancer, ASCVD, and COPD - were \$33,753 ± \$2,026, \$25,212 ±
\$998, \$23,096 ± \$530, and \$21,725 ± \$675 respectively.

151

152 Trends in mean unadjusted annual expenditure among individuals with AF over 2016-2021 are 153 shown in Figure 1. Over the study period, there was a 11.1% (\$2,635) increase in annual total 154 expenditures, 63.8% (\$1,667) increase in outpatient expenditures, 31.6% (\$1,193) increase in 155 office-based visits, 97.8% (\$493) increase in emergency department expenditures, 9.0% (\$133) 156 increase in home health expenditures, and 49.0% (\$485) increase in other expenditures. There 157 was a decrease of 14.6% (\$1,129) in inpatient expenditures and 3.1% (\$208) in medication 158 expenditures. In comparison, among individuals without AF, there was a 23.1% (\$1,464) 159 increase in annual total expenditures, driven by a 41.9% (\$672) increase in office-based 160 expenditures, 87.0% (\$490) increase in outpatient expenditures, 21.1% (\$335) increase in

161	medication expenditures, and 48.0% (\$228) increase in other expenditures. There was a 13.9%
162	(\$214) decrease in inpatient expenditures, 4.9% (\$16) decrease in home health, and a 12.4%
163	(\$30) decrease in ED expenditures.
164	
165	After adjusting for demographics, comorbidities, and survey year, the incremental mean annual
166	healthcare expenditure attributable to AF estimated from the two-part regression model was
167	\$6,188 per person (95% CI \$5,075-\$7,301). With a survey weighted AF population of 3,564,763
168	as shown in Table 1, this translates to an overall national healthcare expenditure of \$22.1 billion
169	per year.
170	
171	Incremental expenditures attributable to AF within subpopulations of individuals with the 4 other
172	common chronic comorbidities of cancer, ASCVD, COPD, and HF were estimated using a
173	gamma regression model for each subpopulation (Table 2). From largest to smallest, the average
174	marginal effects (95% CI) of having AF in addition to cancer, COPD, or ASCVD were \$11,967

(\$4,410-\$19,525), \$8,104 (\$2,594 - \$13,613), and \$6,721 (\$3,684 - \$9,758) respectively. HF did
not significantly impact AF expenditures with an average marginal effect of -\$2,756 (-\$10,048 \$4,535) (Central Illustration).

178

After adjustment for demographics, comorbidities, and survey year in a gamma regression model (Table 3), the variables associated with increased total healthcare expenditure among individuals with AF were modified CCI of  $\geq 2$  [OR 1.95 (95% CI 1.53-2.50), p<0.001] and 1 [OR 1.28 (95% CI 1.07-1.54), p=0.009], uninsured status [OR 1.83 (95% 1.13-2.96), p=0.014], cancer [OR 1.76 (95% CI 1.35-2.29), p<0.001], poor income level [OR 1.39 (95% CI 1.02-1.88), p=0.037],

184	ASCVD	[OR 1.37 (	(95% CI	1.17-1.60).	p<0.0011.	COPD [	OR 1.31 (	(95% CI 1.01-1.69	).
104	ASCVD	OK 1.57 (	93% CI	1.1/-1.00),	p<0.001],	COPD	UK 1.51 (	93% CI 1.01-1	.09

```
185 p=0.039], and later survey year [OR 1.07 (95% CI 1.03-1.12), p=0.002].
```

186

#### 187 **DISCUSSION**

- 188 Individuals with AF had mean unadjusted annual total healthcare expenditures nearly 3 times
- that of individuals without AF and total expenditures increased by 11% from 2016 to 2021. After
- 190 adjustment for demographics, comorbidities, and survey year, the incremental annual
- 191 expenditure was ~\$6,000 per person with AF, translating to over \$22 billion in healthcare
- 192 expenditures annually from AF. Among individuals with AF, a higher comorbidity burden,
- 193 presence of cancer, uninsured status, and a more recent survey year were associated with higher

194 expenditures.

195

196 Our findings build on prior studies focusing on healthcare expenditures in AF. In a systematic 197 review of studies from 1990-2009, Wolowacz et al. found the direct expenditures of AF across 198 the 5 studies from the US to vary from as low as \$2,000 per patient-year to as high as \$14,200 199 (23). In another study, using a database of commercially insured patients from 2017-2020, 200 Deshmukh et al. found mean total annual healthcare expenditure for patients with AF to be much 201 higher at \$63,031 (\$27,896 more than those without AF) (24). Additionally, in a 1999-2002 202 privately insured database for 2 million enrollees, Wu et al. reported that the excess annual direct 203 expenditure of AF was \$12,349 (p<0.001), with individuals with AF having expenditures 204 approximately 5 times higher than individuals without AF (\$15,553 versus \$3,204, respectively) 205 (25).

206

207	In our study, we found mean unadjusted annual healthcare expenditures for individuals with AF
208	to be \$25,241 per person per year, and after adjustment for demographics and comorbidities, the
209	presence of AF was associated with an additional \$6,188 incremental healthcare expenditure.
210	Additionally, although AF is often considered to be a condition associated with other chronic
211	conditions, AF is also, in itself, a significant driver of expenditures. Healthcare expenditures for
212	individuals with AF were noted to be in a similar range to the total expenditures for individuals
213	with other common comorbidities such as ASCVD, cancer, and COPD. With increasing
214	prevalence of AF and healthcare expenditures comparable to other major chronic conditions,
215	healthcare expenditures for AF deserve greater public attention and policy focus.
216	
217	Compared to the wide range of expenditures reported by prior studies, our estimates are likely
218	more accurate and representative of current expenditures among individuals with AF in the US
219	as the MEPS is considered a national standard in assessing expenditures of medical conditions in
220	the population, measuring both direct payments for healthcare services and out-of-pocket
221	payments, and includes participants across all insurance statuses.
222	
223	Inpatient (hospitalization) expenditures were the largest contributor to expenditures among
224	individuals with AF—consistent with prior studies (5,23)—and accounted for nearly a third of
225	the total expenditure. Hospitalizations among individuals with AF are often related to the
226	presence of multiple comorbidities or complications related to AF such as stroke,
227	thromboembolism, and anticoagulant-related issues (24,26). However, use of ablation procedures
228	and cardioversions to maintain sinus rhythm and left atrial appendage for stroke prevention may
229	also be an increasing contributor to hospitalizations. One reason for the increase in total

230 healthcare expenditures from 2016-2021 could be increasing use of catheter ablation strategies 231 for AF patients, which have grown by 10% per year (27). However, studies have suggested that 232 ablation may reduce downstream costs compared to medical therapy. In the Catheter Ablation vs 233 Antiarrhythmic Drug Therapy for Atrial Fibrillation trial (CABANA) trial, catheter ablation of 234 AF was economically attractive compared to drug therapy based on the incremental cost-235 effectiveness ratio of \$57,893 per quality-adjusted life year gained (28). It is possible that over 236 time the increased use of ablations may translate to decreased hospitalization costs. The strength 237 of the ongoing survey design of MEPS can allow periodic reassessment of hospitalization costs. 238 Future studies distinguishing expenditures due to elective vs. emergent hospitalizations can 239 improve our understanding of expenditures related to AF. Ultimately, as hospitalizations 240 contribute significant burden in expenditures with AF (29), they should also be afforded 241 significant policy focus to improve patient care.

242

243 Prescription expenditures were the second largest contributor to AF expenditures. A recent 244 innovation in AF management has been the emergence of DOACs and their use has been 245 increasing use of over the past decade (30). Besides DOACs, increasing antiarrhythmic drug 246 usage may also contribute to increasing prescription expenditures (31). Despite high prescription 247 expenditures, our study showed a small decrease in prescription expenditures of 3.1% (\$208) 248 from 2016-2021. This may be because most DOACs were already approved prior to our study's 249 start year of 2016 (32). With some DOACs potentially becoming available in generic form in the 250 future, prescription expenditures may decrease substantially over the next decade. Furthermore, 251 medications such as DOACs reduce severe bleeding events including intracranial bleeding and 252 left atrial appendage occlusion.

253

254 Among individuals with AF, the mean unadjusted annual total expenditure increased over time 255 by \$2,636, or 11.1%. Over the 2016-2021 study period, there were increases across all medical 256 service categories except for inpatient expenditures (the category with the largest contribution to 257 expenditures), which decreased by 14.6%, and medication expenditures, which decreased by 258 3.1%. A closer look at the trend in inpatient expenditures shows that there was an increasing 259 trend of hospitalization expenditures prior to the COVID-19 pandemic (22.0% from 2016-2019). 260 However, since then, the inpatient expenditures were observed to decrease by 29.9% from 2019-261 2021, which match reported declines in AF admission rates and new diagnoses during COVID-262 19 (33-35). The drivers of this recent decrease are unclear. This may be related to the competing 263 risk of mortality, which was high among the elderly population with COVID-19—especially 264 among those with multiple comorbidities. Alternatively, there may have been systemic declines 265 in hospitalizations or average hospitalization expenditures among individuals with AF. Studies 266 are needed to compare the causes, frequency, and expenditures of hospitalizations among 267 individuals with AF before and after the pandemic.

268

A novel aspect of our study is the evaluation of the incremental expenditures attributable to AF among individuals with other commonly coexisting chronic diseases. Incremental expenditures attributable to AF were greatest in cancer (\$11,967), suggesting that coexistence or development of AF is a significant cost driver among individuals with cancer. This may be related to increased hospitalizations or length of stay and increased prescription expenditures. On the other hand, AF did not change expenditures for individuals with HF, which is surprising given that AF is associated with worse prognosis in HF (36) and can be expected to increase costs. However, a

276 lack of effect on expenditures when these conditions co-exist may potentially be due to an

- 277 overlap in shared medications, treatments for these two chronic cardiac conditions, or
- 278 unidentified confounders in baseline characteristics.

279

280 In the coming years, the total expenditures for individuals with AF may continue to increase.

281 Newer classes of AF medications and the increasing use of procedural and device therapies may

be drivers of expenditures. On the other hand, with more efficacious treatments and monitoring,

there may be reductions in other expenditures, such as decreased hospitalizations. The ongoing

survey and consistent methodology are strengths of using the MEPS database, and allow for

285 close monitoring of patterns of change in expenditures over time.

286

287 Our study has several limitations. First, due to high rates of comorbidities among individuals 288 with AF, there may be residual confounding after multivariable adjustment making it harder to 289 assess independent effects of AF on expenditure. Second, our study overlapped with the COVID-290 19 pandemic from 2019-2021. Thus, there may be short-term changes in expenditure patterns 291 that warrant reassessment in coming years. Third, because the MEPS database lacks information 292 on procedures, we are unable to report expenditures of AF-associated procedures such as 293 ablation and left atrial appendage closure and how they relate to expenditures as they are likely 294 captured as part of inpatient expenditures. MEPS also lacks participant representation from 295 institutionalized individuals including nursing home residents (37). Also, our study does not account for indirect expenditures incurred by individuals, such as income lost due to reduced 296 297 productivity and caregiver expenses. Thus, actual expenditures incurred by individuals with AF 298 may be higher than the direct expenditures reported in the study.

299

300	An additional limitation is that the self-reported nature of MEPS data can lead to underreporting
301	of expenditures. For personal healthcare spending estimates, MEPS data have been reported to
302	be consistently lower than National Health Expenditure Accounts (NHEA) data from the Centers
303	for Medicare and Medicaid Services, which are known as the official estimates of total
304	healthcare spending in the US. Specifically, MEPS reports \$240.3 billion or 17.6% less
305	expenditures than the adjusted NHEA total expenditures (38). These different may be caused by
306	different factors including sampling bias, non-response bias, attrition, and other measurement
307	errors (39).

#### 308 CONCLUSION

309 Individuals with AF have high and increasing healthcare expenditures that amount to over \$22 310 billion in US spending every year. Further, the co-existence of AF among individuals with 311 comorbidities of ASCVD, cancer, and COPD significantly increased expenditures. Given these 312 high expenditures and increasing prevalence, AF warrants increased focus from healthcare policy 313 makers to alleviate financial burden and improve patient outcomes. In parallel, there are 314 continued advancements in AF management, and the resulting improvements in cardiovascular 315 health can lead to reductions in long-term healthcare expenditures. Thus, there is a need to 316 periodically reassess expenditures.

317

#### 319 **PERSPECTIVES**

#### 320 Competency in Systems-Based Practice 1:

- 321 Individuals with AF incur \$25,451 of healthcare expenditures per year and expenditures are
- 322 increasing over time. The incremental expenditure per year attributable to AF is \$6,188 after
- 323 multivariable adjustment. This translates to an overall national healthcare expenditure of \$22.1
- 324 billion per year. AF increases expenditures further among individuals with other chronic
- diseases.

#### 326 Competency in Systems-Based Practice 2:

- 327 Individuals with AF who were surveyed in more recent years, had more comorbidities including
- 328 cancer, ASCVD, and COPD, and were poor and uninsured had higher annual healthcare
- 329 expenditures after multivariable adjustment.

#### 330 Competency in Patient Care and Procedural Skills:

331 Given high expenditures, AF needs increased focus of policy makers. With increased detection

and changes in treatment of AF, expenditures need continual assessments.

### 333 Translational Outlook:

This study, which uses an all-payer nationally representative annual cross-sectional survey of

medical expenditures of the United States civilian noninstitutionalized population, found that 1)

- individuals with AF had mean unadjusted annual total healthcare expenditures nearly 3 times
- that of individuals without AF, with total expenditures increasing by 11.1% from 2016 to 2021;
- 338 2) after multivariable adjustment, the incremental annual expenditure was approximately \$6,000
- per person with AF, translating to over \$22 billion in healthcare expenditures annually; and 3)
- 340 among individuals with AF, a higher comorbidity burden, presence of cancer, ASCVD, or
- 341 COPD, uninsured status, poor income level, and later survey year were associated with higher

- 342 expenditures. With an aging US population and new screening and management methods, further
- 343 studies are needed to reassess trends in healthcare expenditures in AF over time.

344

# 346 ACKNOWLEDGEMENTS

347 We thank the Yale StatLab student consultant team for their statistical advice.

# 349 **REFERENCES**

- 350
- January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:e1-76.
- Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and
  future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J
  Cardiol 2013;112:1142-7.
- Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in the 21st Century. Circulation Research 2020;127:4-20.
- Benjamin EJ, Muntner P, Alonso A et al. Heart Disease and Stroke Statistics-2019
   Update: A Report From the American Heart Association. Circulation 2019;139:e56-e528.
- 362 5. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total
  363 incremental health care costs in patients with atrial fibrillation in the United States. Circ
  364 Cardiovasc Qual Outcomes 2011;4:313-20.
- Burdett P, Lip GYH. Atrial fibrillation in the UK: predicting costs of an emerging
  epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs.
  Eur Heart J Qual Care Clin Outcomes 2022;8:187-194.
- 368 7. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of
  369 Atrial Fibrillation on the Risk of Death. Circulation 1998;98:946-952.
- Chamberlain AM, Alonso A, Gersh BJ et al. Multimorbidity and the risk of
   hospitalization and death in atrial fibrillation: A population-based study. American Heart
   Journal 2017;185:74-84.
- Jani BD, Nicholl BI, McQueenie R et al. Multimorbidity and co-morbidity in atrial
  fibrillation and effects on survival: findings from UK Biobank cohort. EP Europace
  2017;20:f329-f336.
- Cohen JW, Cohen SB, Banthin JS. The medical expenditure panel survey: a national
  information resource to support healthcare cost research and inform policy and practice.
  Med Care 2009;47:S44-50.
- MEPS-HC Response Rates by Panel Display page in Printer Friendly Format printer friendly. Agency for Healthcare Research and Quality: Retrieved from:
   https://meps.ahrq.gov/survey\_comp/hc\_response\_rate.jsp.
- 382 12. Survey MEP. Question: Does the DUPERSID variable uniquely identify a person in the
   383 MEPS survey? : Agency for Healthcare Research and Quality: Retrieved from
   384 <u>https://meps.ahrq.gov/about\_meps/faq\_answers.jsp?FAQID=127&ChooseCategory=5&k</u>
   385 evword=.
- 386 13. MEPS HC-231: 2021 Medical Conditions. Agency for Healthcare Research and Quality:
   387 Retrieved from: <u>https://meps.ahrq.gov/data\_stats/download\_data/pufs/h231/h231doc.pdf</u>.
- MEPS HC-192 2016 Full Year Consolidated Data File. Agency for Healthcare Research and Quality, August 2018:Retrieved from

390 <u>https://meps.ahrq.gov/data\_stats/download\_data/pufs/h192/h192doc.pdf</u>.


- MEPS HC-209 2018 Full Year Consolidated Data File. Agency for Healthcare Research and Quality, August 2020:Retrieved from:
- 393 <u>https://meps.ahrq.gov/data\_stats/download\_data/pufs/h209/h209doc.pdf</u>.

394	16.	MEPS HC-231 2021 Medical Conditions. Agency for Healthcare Research and Quality,
395		August 2023:Retrieved from
396		https://meps.ahrq.gov/data_stats/download_data/pufs/h209/h209doc.pdf.
397	17.	MEPS HC-036: 1996-2015 Pooled Linkage Variance Estimation File - 4.0 Adjustment of
398		Analytic Weight Variable. Agency for Healthcare Research and Quality (AHRQ),
399		September 2017: Retrieved from:
400		https://meps.ahrq.gov/data_stats/download_data/pufs/h36/h36u15doc.shtml#40Other.
401	18.	Stagg V. Charlson comorbidity index macro. University of Calgary:Retrieved from
402		http://fmwww.bc.edu/RePEc/bocode/c/charlson.html.
403	19.	William W. Yu SM. Examination of Skewed Health Expenditure Data from the Medical
404		Expenditure Panel Survey (MEPS). Agency for Healthcare Research and Quality
405		Working Paper No. 04002, 2004.
406	20.	Klein S, Jiang S, Morey JR et al. Estimated Health Care Utilization and Expenditures in
407		Individuals With Heart Failure From the Medical Expenditure Panel Survey. Circ Heart
408		Fail 2021;14:e007763.
409	21.	Bhatnagar R, Fonarow GC, Heidenreich PA, Ziaeian B. Expenditure on Heart Failure in
410		the United States: The Medical Expenditure Panel Survey 2009-2018. JACC Heart Fail
411		2022;10:571-580.
412	22.	TABLE 1. ICD-9-CM and ICD-10 Coding Algorithms for Charlson Comorbidities.
413		Manitoba Centre for Health Policy: University of Manitoba.
414	23.	Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda J-G, Van Gelder IC. The cost
415		of illness of atrial fibrillation: a systematic review of the recent literature. EP Europace
416		2011;13:1375-1385.
417	24.	Deshmukh A, Iglesias M, Khanna R, Beaulieu T. Healthcare utilization and costs
418		associated with a diagnosis of incident atrial fibrillation. Heart Rhythm O2 2022;3:577-
419		586.
420	25.	Wu EQ, Birnbaum HG, Mareva M et al. Economic burden and co-morbidities of atrial
421		fibrillation in a privately insured population. Curr Med Res Opin 2005;21:1693-9.
422	26.	Nesheiwat Z, Goyal A, Jagtap M. Atrial Fibrillation. StatPearls. Treasure Island (FL)
423		ineligible companies. Disclosure: Amandeep Goyal declares no relevant financial
424		relationships with ineligible companies. Disclosure: Mandar Jagtap declares no relevant
425		financial relationships with ineligible companies.: StatPearls Publishing. Copyright ©
426		2023, StatPearls Publishing LLC., 2023.
427	27.	Thording L. EP Single-Use Device Reprocessing by the Numbers. Innovate Health.
428	28.	Chew DS, Li Y, Cowper PA et al. Cost-Effectiveness of Catheter Ablation Versus
429		Antiarrhythmic Drug Therapy in Atrial Fibrillation: The CABANA Randomized Clinical
430		Trial. Circulation 2022;146:535-547.
431	29.	Agarwal MA, Fonarow GC, Ziaeian B. National Trends in Heart Failure Hospitalizations
432	•	and Readmissions From 2010 to 2017. JAMA Cardiol 2021;6:952-956.
433	30.	Navar AM, Kolkailah AA, Overton R et al. Trends in Oral Anticoagulant Use Among
434		436 864 Patients With Atrial Fibrillation in Community Practice, 2011 to 2020. J Am
435	21	Heart Assoc 2022;11:e026723.
436	31.	Markman TM, Geng Z, Epstein AE et al. Trends in Antiarrhythmic Drug Use Among
437		Patients in the United States Between 2004 and 2016. Circulation 2020;141:937-939.

438	32.	Chew DS, Wilton SB. Clinical Trials for Atrial Fibrillation—What Do We Know? In:
439		Vasan RS, Sawyer DB, editors. Encyclopedia of Cardiovascular Research and Medicine.
440		Oxford: Elsevier, 2018:630-642.
441	33.	Ueberham L, König S, Pellissier V et al. Admission rates and care pathways in patients
442		with atrial fibrillation during the COVID-19 pandemic—insights from the German-wide
443		Helios hospital network. European Heart Journal - Quality of Care and Clinical
444		Outcomes 2021;7:257-264.
445	34.	Hernandez I, He M, Guo J et al. COVID-19 pandemic and trends in new diagnosis of
446		atrial fibrillation: A nationwide analysis of claims data. PLoS One 2023;18:e0281068.
447	35.	Ubaid MF, John K, Daoudi S et al. PO-01-092 NATIONWIDE TRENDS IN
448		HOSPITALIZATIONS FOR ATRIAL FIBRILLATION IN THE U.S. BEFORE AND
449		DURING THE OUTBREAK OF THE COVID PANDEMIC. Heart Rhythm
450		2024;21:S210.
451	36.	Chamberlain AM, Redfield MM, Alonso A, Weston SA, Roger VL. Atrial fibrillation
452		and mortality in heart failure: a community study. Circ Heart Fail 2011;4:740-6.
453	37.	MEPS Sample Persons In-Scope for Part of the Year: Identification and Analytic
454		Considerations. Medical Expenditure Panel Survey, April 2005: Retrieved from:
455		https://meps.ahrq.gov/about_meps/hc_sample.shtml.
456	38.	Bernard D, Cowan C, Selden T, Cai L, Catlin A, Heffler S. Reconciling medical
457		expenditure estimates from the MEPS and NHEA, 2007. Medicare Medicaid Res Rev
458		2012;2.
459	39.	Aizcorbe A, Liebman E, Pack S, Cutler DM, Chernew ME, Rosen AB. Measuring health
460		care costs of individuals with employer-sponsored health insurance in the U.S.: A
461		comparison of survey and claims data. Stat J IAOS 2012;28:43-51.
462		
463		
464		
465		

#### Figure 1: Trends in Healthcare Expenditures over Time for Individuals with AF


- This bar graph shows the trends in mean unadjusted annual total healthcare expenditures for
- individuals with AF broken down by medical service category from 2016 to 2021.



# 474 Central Illustration: Incremental Expenditures with AF Overall and Specific to Individuals

#### 475 with Other Chronic Comorbidities

- 476 This figure shows the incremental expenditures of AF alone and among individuals with cancer,
- 477 ASCVD, COPD, and HF. Made with BioRender.com (see Supplemental File 1 for publication
- 478 license). AF = Atrial Fibrillation. ASCVD = Atherosclerotic Cardiovascular Disease. COPD =
- 479 Chronic Obstructive Pulmonary Disease. HF = Heart Failure.



# 483 Table 1: Demographics, Comorbidities, and Annual Expenditures of Individuals with and

# 484 without AF from 2016-2021

Variable	All	AF	Non-AF	P Value			
Average Annual Weighted Population, N	248,067,064	3,564,763	244,502,302				
Average Annual Sample Size, n	22,583	317	22,266				
Age Categories (%)							
18-44 years old	45.8	2.4	46.4				
45-64 years old	33.1	19.3	33.3	<0.001			
65-84 years old	18.8	64.0	18.2				
≥85 years old	2.3	14.3	2.2				
Sex (%)							
Female	51.7	45.7	51.8	<0.001			
Male	48.3	54.3	48.2				
Race (%)							

Variable	All	AF	Non-AF	P Value		
Non-Hispanic White	62.7	89.0	62.3			
Hispanic	16.4	3.3	16.6			
Non-Hispanic Black	11.9	4.6	12.0			
Non-Hispanic Asian and Other/Mixed	9.1	3.2	9.1	<0.001		
Race						
Marital Status (%)						
Married	51.7	59.7	51.6			
Widowed/Divorced/ Separated	19.4	34.5	19.2	<0.001		
Never Married	28.9	5.9	29.2			
Education Level (%)						
GED/High School Diploma	45.0	50.7	44.9	-0.001		
Bachelor's Degree	20.9	14.6	21.0	<0.001		
Master/Doctorate	12.3	19.4	12.2			

Variable	All	AF	Non-AF	P Value
Other Degree	10.1	9.3	10.1	
No Degree	11.8	6.1	11.9	
Census Region (%)				
Northeast	17.5	21.4	17.4	
Midwest	20.8	25.5	20.8	
South	37.9	37.3	38.0	<0.001
West	23.7	15.9	23.9	
Household Income Le	vel (%)			
Poor/Negative	10.4	7.5	10.5	
Near Poor	3.7	3.4	3.7	
Low Income	11.9	13.9	11.9	<0.001
Middle Income	28.5	28.0	28.5	
High Income	45.4	47.2	45.4	
Insurance Status (%)				
Private	58.7	16.8	59.3	<0.001

All	AF	Non-AF	P Value
12.5	78.2	12.7	
7.6	4.3	7.7	
21.1	0.7	20.2	
		L	
83.4	50.6	83.9	
11.0	26.3	10.8	
5.6	23.0	5.3	<0.001
5.6	34.7	5.2	<0.001
0.7	7.0	0.6	<0.001
3.5	12.6	3.4	<0.001
2.3	9.5	2.2	<0.001
Survey Year (%)			
16.4	15.3	16.4	
16.6	14.4	16.6	
	12.5 7.6 21.1 83.4 11.0 5.6 5.6 0.7 3.5 2.3 16.4	12.5 $78.2$ $7.6$ $4.3$ $21.1$ $0.7$ $83.4$ $50.6$ $11.0$ $26.3$ $5.6$ $23.0$ $5.6$ $23.0$ $5.6$ $34.7$ $0.7$ $7.0$ $3.5$ $12.6$ $2.3$ $9.5$ $16.4$ $15.3$	12.578.212.7 $7.6$ $4.3$ $7.7$ $21.1$ $0.7$ $20.2$ $83.4$ $50.6$ $83.9$ $11.0$ $26.3$ $10.8$ $5.6$ $23.0$ $5.3$ $5.6$ $34.7$ $5.2$ $0.7$ $7.0$ $0.6$ $3.5$ $12.6$ $3.4$ $2.3$ $9.5$ $2.2$ $16.4$ $15.3$ $16.4$

Variable	All	AF	Non-AF	P Value
2018	16.7	15.9	16.7	0.014
2019	16.7	18.2	16.7	
2020	16.8	16.4	16.8	
2021	16.8	19.8	16.8	
Annual Unadjusted Ex	xpenditures (Mean	$1 \pm SD)^*$		
Total	\$7,392 ± \$67	\$25,451 ± \$1,100	\$7,129 ± \$66	<0.001
Inpatient	\$1,598 ± \$33	\$7,975 ± \$733	\$1,506 ± \$32	<0.001
Prescription	\$1,822 ± \$34	\$6,505 ± \$372	\$1,753 ± \$34	<0.001
Office-Based	\$1,918 ± \$24	\$4,716 ± \$247	\$1,877 ± \$24	<0.001
Outpatient	\$801 ± \$19	\$2,867 ± \$314	\$771 ± \$19	<0.001
Home Health <sup><math>\dagger</math></sup>	\$372 ± \$15	\$1,345 ± \$138	\$357 ± \$15	<0.001
ED	\$246 ± \$4	\$715 ± \$90	\$239 ± \$4	<0.001
Other <sup>‡</sup>	\$637 ± \$6	\$1,329 ± \$66	\$626 ± \$7	<0.001

485

Values are % or mean  $\pm$  standard deviation (SD). COPD = Chronic Obstructive Pulmonary

- 487 Educational Development. ED = Emergency Department.
- 488 <sup>\*</sup>Expenditures are reported in inflation-adjusted 2021 US dollars.

<sup>486</sup> Disease. HF = Heart Failure. ASCVD = Atherosclerotic Cardiovascular Disease. GED = General

- <sup>†</sup>Home health expenditures are summed as home health agency and home health non-agency
- 490 expenditure MEPS variables.
- <sup>‡</sup>Other expenditures are summed as dental, vision, and other expenditure MEPS variables.

492

493

### 495 Table 2: Incremental Expenditures with AF among Individuals with Other Common

#### 496 Chronic Comorbidities from Gamma Regression

Sub population	Average Annual Sample Size, n	Average Annual Weighted Population, N	AF Prevalence	Incremental Expenditure with AF (95% CI)
Cancer*	814	8,706,309	5.1%	\$11,967 (\$4,410-\$19,525)
COPD	581	5,705,185	5.9%	\$8,104 (\$2,594 - \$13,613)
ASCVD	1,388	13,846,252	8.9%	\$6,721 (\$3,684 - \$9,758)
HF	176	1,640,324	15.3%	-\$2,756 (-\$10,048 - \$4,535)

Values are average marginal effect (95% CI) of having AF from a gamma regression of
individuals with a given comorbidity. Expenditures are reported in inflation-adjusted 2021 US
dollars. CI = Confidence Interval. AF = Atrial Fibrillation. COPD = Chronic Obstructive
Pulmonary Disease. ASCVD = Atherosclerotic Cardiovascular Disease. HF = Heart Failure.
\*Due to low sample size in subcategories, the insurance status variable was excluded from the
gamma regression model for individuals with cancer to enable convergence.

503

# 505 Table 3: Factors Associated with Increased Total Healthcare Expenditures Among

# 506 Individuals with AF from Gamma Regression

	OR (95% CI)	P Value
Age Categories		
65-84 years old (Ref)		
18-44 years old	1.37 (0.35-5.34)	0.648
45-64 years old	0.85 (0.33-2.16)	0.729
≥85 years old	1.10 (0.89-1.34)	0.381
Sex		
Male (Ref)		
Female	0.92 (0.79-1.07)	0.274
Survey Year	1.07 (1.03-1.12)	0.002
Race/Ethnicity		
Non-Hispanic White (Ref)		
Hispanic	0.98 (0.73-1.32)	0.896

	OR (95% CI)	P Value
Non-Hispanic Black	0.90 (0.63-1.27)	0.545
Non-Hispanic Asian and Other/Mixed	1.15 (0.65-2.04)	0.638
Modified CCI		
0 (Ref)		
1	1.28 (1.07-1.54)	0.009
≥2	1.95 (1.53-2.50)	<0.001
Comorbidities		
Cancer	1.76 (1.35-2.29)	<0.001
ASCVD	1.37 (1.17-1.60)	<0.001
COPD	1.31 (1.01-1.69)	0.039
HF	1.20 (0.95-1.52)	0.124
Education		
GED/HS Grad (Ref)		
No Degree	0.79 (0.59-1.06)	0.110

	OR (95% CI)	P Value
Bachelor's	1.19 (0.93-1.54)	0.168
Master/Doctorate	1.20 (0.95-1.51)	0.124
Other Degree	0.83 (0.66-1.03)	0.096
Marital Status		
Married (Ref)		
Widowed/ Divorced/ Separated	1.12 (0.97-1.29)	0.108
Never Married	1.04 (0.76-1.43)	0.798
Household Income Level		
High Income (Ref)		
Poor	1.39 (1.02-1.88)	0.037
Near Poor	1.11 (0.86-1.45)	0.398
Low Income	1.04 (0.84-1.28)	0.724
Middle Income	1.14 (0.98-1.33)	0.099
Insurance Status		
Medicare (Ref)		

	OR (95% CI)	P Value
Private	1.78 (0.66-4.78)	0.254
Other Public	1.18 (0.42-3.28)	0.749
Uninsured	1.83 (1.13-2.96)	0.014

507 OR = Odds Ratio. CI = Confidence Interval. CCI = Charlson Comorbidity Index. COPD =

508 Chronic Obstructive Pulmonary Disease. HF = Heart Failure. ASCVD = Atherosclerotic

509 Cardiovascular Disease. AF = Atrial Fibrillation. GED = General Education Development. Grad

510 = Graduate. HS = High School. Ref = Reference.

# 512 Supplemental Table 1: ICD-10 Code Definitions for Other Chronic Comorbidities


513

Medical Condition	ICD-10 Codes
Heart Failure	I09, I11, I13, I25, I42, I43, I50, P29
Atherosclerotic Cardiovascular Disease	H34, I20-I25, I60-I69, G45, G46, I70, I71, I73, I77, I79, K55, Z95
Cancer	C00-C26, C30-C34, C37-C41, C43, C45-C58, C60-C76, C77-C80, C81- C85, C88, C90-C97
Chronic Obstructive Pulmonary Disease	J41-J44

514 ICD = International Classification of Diseases.

515

516



**Central Illustration:** This figure shows the incremental expenditures of AF alone and among individuals with cancer, ASCVD, COPD, and HF. Made with BioRender.com (see Supplemental File 1 for publication license). AF = Atrial Fibrillation. ASCVD = Atherosclerotic Cardiovascular Disease. COPD = Chronic Obstructive Pulmonary Disease. HF = Heart Failure.